Hook
Chart Industries (GTLS) is trading at $207.76 and sits just below a $210-per-share acquisition offer from Baker Hughes. On the surface this is a classic merger-arbitrage play: buy the stock, collect the spread, and wait for the deal to close. But Chart is more than an acquisition target. Its cryogenic equipment and specialty tanks make it a de facto infrastructure owner for helium logistics - a commodity increasingly described as "blue gold" for its scarcity and strategic role in nascent technologies like quantum computing and advanced sensing.
Thesis
Take the spread to capture the near-term arbitrage while retaining optionality on Chart's exposure to long-term helium and cryogenic demand. The deal consideration of $210 gives a clear near-term upside; at the same time, Chart's $6.05 billion backlog, $1.01 billion adjusted EBITDA milestone, and an enterprise value of roughly $13.26 billion make the company attractive on an EV/EBITDA of ~14.6. If the Baker Hughes deal closes, the market realizes that buyout price as fair value; if not, Chart's fundamentals and market position in helium and cryogenic systems underpin a reversion toward its 52-week high and beyond.
Why the market should care
Chart manufactures engineered cryogenic equipment used for storage, distribution, liquefaction, and purification of industrial gases. Those capabilities are central to LNG, hydrogen, medical gases, and specialty gas markets. Helium is an important niche: it powers low-temperature refrigeration for superconducting magnets and dilution refrigerators used in quantum research. Tight helium supply, rising demand from both industrial and scientific users, and greater LNG infrastructure spending have combined to lift the addressable market for cryogenic equipment. A March 2026 market study projects the cryogenic equipment market growing from $14.74 billion in 2025 to $22.96 billion by 2030 at a 9.3% CAGR.
Company snapshot and key numbers
- Market cap: roughly $9.94 billion.
- Enterprise value: about $13.26 billion; EV/EBITDA: ~14.64.
- Adjusted EBITDA milestone: $1.01 billion (reported by the company in recent coverage).
- Backlog: ~$6.05 billion (company-reported record backlog).
- Free cash flow (most-recent): $202.8 million.
- Current share price: $207.76; Baker Hughes offer: $210.00 per share.
- 52-week range: low $116.74 (04/21/2025), high $208.51 (04/14/2026).
Valuation framing
At a $210 takeout, the implied equity value is in line with the recent deal consideration. On an EV/EBITDA of 14.6, the multiple sits below what larger industrial consolidation targets often command when strategic synergies are included; that suggests the buyer saw room for operational or market-driven upside. Traditional P/E metrics are distorted here by a low trailing EPS ($0.28) and a very high P/E figure, which reflects earnings timing rather than operating weakness. The balance sheet measures - current ratio ~1.36 and debt-to-equity ~1.14 - show leverage that is manageable for a capital goods business but relevant for integration risk in a large strategic acquisition.
Catalysts
- Regulatory and shareholder approval timeline for the Baker Hughes acquisition - expected to close mid-2026; every regulatory filing or shareholder vote moves the arbitrage value.
- Baker Hughes debt financing completed on 03/05/2026: a $6.5 billion U.S. offering and a billion euro tranche were priced to fund the deal, reducing financing uncertainty.
- Operational momentum: record third-quarter orders and a $6.05 billion backlog support revenue visibility and strengthen the buyer thesis for retention of Chart's capabilities.
- Macro demand: continued LNG buildout and hydrogen infrastructure investments will keep cryogenic equipment demand elevated over the next decade.
Trade plan
This is a hybrid trade: merger-arbitrage core plus a satellite bet on post-close fundamentals. Plan and risk controls below are built around the merger timeline and Chart's role in helium/cryogenic markets.
| Position | Entry | Target | Stop | Horizon |
|---|---|---|---|---|
| Core arbitrage long | $207.76 | $210.00 | $202.00 | Long term (180 trading days) |
Rationale: the entry sits at market; the $210 target is the announced takeout. The $202 stop limits downside should the deal show early signs of failure or a major adverse regulatory development. The horizon is long term (180 trading days) because closing is expected mid-2026 and we want to carry the position through regulatory review and shareholder votes. If the deal closes early, tighten risk or take profits; if the spread widens while filings progress, consider scaling in.
Technical and market-flow context
Volume and short activity warrant attention. Two-week average volumes point to robust liquidity (multi-million share average), and short-volume reads through mid-April show elevated short selling on heavier-volume days. RSI sits in neutral to slightly bullish territory (~55.9) and MACD shows bullish momentum. Days-to-cover on short interest recently fell near 2.16, indicating limited potential for a protracted short squeeze, but heavy intraday short volume has created volatility spikes in the past.
Risks and counterarguments
- Deal failure or renegotiation: regulatory pushback, a competing bid, or a hostile shareholder action could derail or reprice the deal. A failed deal would likely reprice shares materially below $210, creating downside well beyond the planned stop.
- Integration and financing risk: while Baker Hughes completed debt offerings on 03/05/2026 to fund the buyout, challenges in integration or unexpected financing costs could lead to renegotiation or a drawn-out close timeline.
- Macro slowdown in cryogenic demand: a sharp pause in LNG or industrial gas investment would weaken Chart's long-term end markets, reducing the attractiveness of the business absent the buyout.
- Helium-market volatility: helium is scarce and pricing can be lumpy. Supply shocks or substitution in critical applications could change demand dynamics for Chart's specialty products.
- Liquidity and spreads: while average volumes are healthy, merger-arb spreads can widen quickly; traders adding late may face higher execution and borrowing costs.
Counterargument: Critics will point out that Chart is trading just below takeout, leaving a tiny spread that barely compensates for deal risk and time. That is fair: the immediate arbitrage margin is slim and might not cover financing or opportunity cost for some investors. My view is that the combination of finalized debt financing by the buyer, strong backlog and EBITDA, and the strategic value of Chart's cryogenic capabilities make the probability-weighted payoff acceptable for a disciplined, size-limited position, especially if you plan to exit at close or on a verified regulatory clearance.
What would change my mind
I'll reduce conviction or close the position if any of the following happens: (1) substantive regulatory inquiry is disclosed that could materially delay or block the deal; (2) Baker Hughes withdraws or materially revises the $210 offer; (3) material deterioration in order intake or backlog beyond a reasonable quarter-to-quarter fluctuation; (4) a credible competing bidder appears that pushes the process into a contested auction where timelines and outcomes become uncertain.
Conclusion
Chart Industries sits at the nexus of a near-term, low-spread merger arbitrage and a longer-term structural exposure to cryogenics and helium - markets that look set to grow with LNG, hydrogen, and advanced technologies. The trade here is straightforward: buy a modest size at $207.76, set a protective stop at $202, and capture the $210 takeout or exit on confirmed regulatory news. This approach balances deal-risk management with exposure to the core business that underpins Chart's strategic value to an industrial buyer. Keep position sizing prudent and monitor regulatory milestones closely; if the deal closes, the arbitrage will have done its work and the buyer will inherit the industrial optionality of a leader in a growing space.